hiv vaccines in development

8/14/2019 HIV Vaccines in Development

http://slidepdf.com/reader/full/hiv-vaccines-in-development 1/7

HIV vaccines i

Septe

Cat No: VADIP001CAT NO: VAVS017

n development

ber 2009

©VacZine Analytics 2009



2

HIV vaccines currently in development

Status Company Partner Interventi

AlphaVax AVX-201 N/A

Bavarian Nordic mBN120B

Celldex Rockefeller Univ. CDX-2401

Crucell

Beth IsraelDeaconess MedicalCenter Ad26-ENVA.01

CytoGenix

C tos Biotechnolo

NEW Genetic Immunity DermaVir patch

GenexineSeoul National Univ.Hospital GX-120

GenPhar

J S7 DNA and

NEW GeoVax MVA/HIV62

NEW GSK Biologicals GSK732461

NEW

Inovio (VGX

Pharmaceuticals) HVTN PENNVAX-B

NEW Inovio (VGX Pharmaceuticals) PENNVAX-G/GP

NEW

International AIDSVaccine Initiative

University of Rochester MedicalCenter/Crucell Ad35-GRIN/ENV

Karolinska Institutet Vical

Maxygen

NEW NIAID DNA prime-rAd5

Source: Vaccine Pipeline/IP review, CAT No: VAVS016, published September 2009

NEW =trial started between November 2008 and September 2009

n Most Clinical Clinical trial link

advanced

Phase

trial start

date

Active preclinical

Phase I Oct-08 http://ClinicalTrials.gov/show/NCT00623259

Active preclinical

Phase I J un-08 http://ClinicalTrials.gov/show/NCT00618605

Active preclinical

Active reclinical

Phase II Apr-09 http://ClinicalTrials.gov/show/NCT00918840

Phase I J an-07

Active preclinical

Phase II J an-09 http://clinicaltrials.gov/show/NCT00820846

Phase I Feb-09 http://ClinicalTrials.gov/show/NCT00814762

Active preclinical

Active preclinical

Phase I Mar-09 http://ClinicalTrials.gov/show/NCT00851383

Active preclinical

Active preclinical

©VacZine Analytics 2009. All rights reserved.

Phase II Mar-09 http://ClinicalTrials.gov/show/NCT00865566



3

HIV vaccines currently in developmentStatus Company Partner Interventi

NEW NIAID

DNA prime(pGA2/JS7)/MV

(HIV62)

NIAID Ad35-rAd5

Novartis Vaccines NIH Trimeric gp140 svaccine

Novavax NIH

ALVAC-HIVvCP1521/VaxGe

Sanofi Pasteur NIH gp120 B/E

Select Vaccines/Hepgenics

NEW

University of Pennsylvania NIH PENNVAX-B

University of Pennsylvania PENNVAX-B

Variation Biotechnologies Inc. VLP-0012M

VaxOnco (Pharmexa) EP-1090

NEW VaxOnco (Pharmexa) EP-1233

Source: Vaccine Pipeline/IP review, CAT No: VAVS016, published September 2009

NEW =trial started between November 2008 and September 2009

=Recent trial indicating partial protection against infection

cont..)n Most Clinical Comments

a vance

Phase

r a s ar

date

Phase II J an-09 http://ClinicalTrials.gov/show/NCT00820846

Phase I J an-09 http://ClinicalTrials.gov/show/NCT00801697

bunit Terminated Sep-06 http://ClinicalTrials.gov/show/NCT00369031

Active preclinical

Phase III Oct-03 http://ClinicalTrials.gov/show/NCT00223080

Possible preclinical

Phase I Oct-07 http://ClinicalTrials.gov/show/NCT00528489

Phase I Sep-08 http://ClinicalTrials.gov/show/NCT00775424

Active preclinical

Phase I Aug-05 http://ClinicalTrials.gov/show/NCT00141024

Phase I J an-07 http://ClinicalTrials.gov/show/NCT00428337




4

Methodology

Pipeline Review

n ormaton was source rom ompany annua reports, press reeases, an predevelopment for the European and US markets. Coverage in other countries shalthough these are only indicative of current early stage activity as disclosure vaare not covered. BLA and MAA submissions were calculated based on an analyvaccine projects listed in clinicaltrials.gov. Timings were validated though analys

range for programs was derived from clinical trial recruitment data listed in Clinic.

were checked from 27-31 J uly 2009. Clinical trials not yet open for recruitment a

Abbreviations

SC=Subcutaneous administration;Conj=conjugated polysaccharide/toxoid; IM

Intranasal administration; PS=Polysaccharide only; ID=intradermal administrati

sentatons; ncatra s.gov an t e . e pro ect ocuse on pro ucts nuld not be considered fully comprehensive. Preclinical programs are includedies considerably by company. Therapeutic vaccines for non-infectious diseasesis of the phase I, phase II and Phase III clinical development times of 300is of company annual reports, press releases, and presentations. The target age

altrials.gov. Age ranges shown are approximate. This database includes. , ,

of J uly 2009 are assumed to start enrollment in August 2009.

intramuscular administrationLAIV=Live attenuated inactivated virus; IN=on; Recomb=Recombinant/Subunit/Protein fusion/Virosomes/VLP; Inj=IM, SC,




Disclaimer

All rights reserved

in any form without the written permission of the pAdvantage Ltd).

The facts presented within this document, at the timewere gathered ingood faith fromboth primary and secthe position to assure that the facts are guaranteed.actions basedupon facts or recommendations present

,ublisher VacZine Analytics (a division of Assay

of its production, were believed to be correct andndary sources. VacZine Analytics is notalways inVacZine Analytics cannot be held liable for anyd within this document.

hiv vaccines in development

Documents